The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | MRD-guided treatment with ibrutinib and venetoclax for CLL in the FLAIR trial
Talha Munir, MBBS, Leeds Teaching Hospitals NHS Trust, Leeds, UK, comments on the FLAIR study (ISRCTN01844152), investigating a measurable residual disease (MRD)-driven approach to the administration of ibrutinib and venetoclax for patients with chronic lymphocytic leukemia (CLL). This study shows that the majority of patients maintained MRD negativity, with few relapses, suggesting that MRD-driven therapy can induce good remissions in most patients with CLL when combining ibrutinib and venetoclax. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
So I also presented the data on FLAIR study, which is a UK study where we were looking at a combination of ibrutinib and venetoclax given in an MRD-driven way. The patients were receiving between two to six years of this combination. In this update, we are showing that the patients who respond early to the therapy are the patients who have got IGHV unmutated status and also they have got low tumor bulk after nine weeks of ibrutinib therapy...
So I also presented the data on FLAIR study, which is a UK study where we were looking at a combination of ibrutinib and venetoclax given in an MRD-driven way. The patients were receiving between two to six years of this combination. In this update, we are showing that the patients who respond early to the therapy are the patients who have got IGHV unmutated status and also they have got low tumor bulk after nine weeks of ibrutinib therapy. What we are also sharing with our colleagues is the MRD durability when we’re using this combination and what we find is that majority of the patients, in fact 146 patients have continued to maintain MRD negativity. There have been few MRD relapses but these patients have been restarted on therapy as well. So the data further shows us that the MRD-driven therapy probably does help to induce good remissions in majority of the CLL patients where we combine ibrutinib and venetoclax together. Lastly, the safety of the combination still looks pretty good with this combination and further update.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Janssen, AbbVie, AstraZeneca, Alexion, Gilead: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Morphosys: Membership on an entity’s Board of Directors or advisory committees.
